BioCryst Achieves First-Ever Full-Year Profitability, Reports Strong ORLADEYO Growth, and Positive Phase 3 Data for Navenibart

summarizeSummary

BioCryst Pharmaceuticals reported its first full year of GAAP profitability in 2025, driven by strong ORLADEYO revenue growth, and announced positive interim Phase 3 results for navenibart, a key asset from its recent Astria Therapeutics acquisition.

check_boxKey Events

• Achieved First-Ever Full-Year GAAP Profitability

  Reported net income of $263.8 million for 2025, a historic milestone for the company, marking its first full year of GAAP profitability.

• Strong ORLADEYO Revenue Growth

  Full-year 2025 ORLADEYO net revenue reached $601.8 million, a 38% year-over-year increase, exceeding preliminary guidance.

• FDA Approval for Pediatric ORLADEYO

  Received FDA approval for an oral pellet formulation of ORLADEYO for HAE patients aged 2 to <12 years, expanding the drug's market.

• Highly Positive Navenibart Phase 3 Data

  Interim results from the ALPHA-SOLAR trial for navenibart (acquired from Astria Therapeutics) showed robust HAE attack suppression with over 90% reduction, significantly de-risking this late-stage pipeline asset.

auto_awesomeAnalysis

This 8-K marks a significant turning point for BioCryst, as the company achieved full-year GAAP profitability for the first time in its history, reporting a net income of $263.8 million for 2025. This financial milestone is underpinned by robust performance of its flagship drug, ORLADEYO, which saw net revenue reach $601.8 million, exceeding prior preliminary estimates. Furthermore, the company received FDA approval for a pediatric formulation of ORLADEYO, expanding its market reach. A major highlight is the highly positive interim Phase 3 results for navenibart, acquired through the Astria Therapeutics acquisition. The ALPHA-SOLAR trial demonstrated sustained, robust HAE attack suppression with over 90% reduction, significantly de-risking this pipeline asset and bolstering BioCryst's long-term growth trajectory in hereditary angioedema. The maintained 2026 revenue guidance further signals management's confidence. Investors should view this filing as a strong validation of BioCryst's strategy and execution, with both current product performance and future pipeline prospects showing significant strength.